Idiosyncratic Liver Injury Due to Levocetirizine

Giuseppe Annunziata, MD1, Imai Mayuko, MD2, and Mary Barbara, MD1

1Department of Medicine, University of Texas Health San Antonio, San Antonio, TX
2Department of Pathology, University of Texas Health San Antonio, San Antonio, TX

ABSTRACT

Levocetirizine is an over-the-counter non-sedating antihistaminic agent commonly used to treat allergic diseases. Clinically significant acute liver injury has been very rarely associated with its use. Only 2 cases of acute liver injury associated with levocetirizine have been reported in the literature. We describe the case of a 67-year-old man who developed clinically significant acute hepatic injury after using levocetirizine. On the liver biopsy, there were histological findings of periportal inflammation and prominent cholestatic injury; such findings are consistent with those previously described in another similar case.

INTRODUCTION

Drug-induced liver injury (DILI) is among the most common causes of acute liver injury (ALI) and acute liver failure (ALF) in the United States.1 Levocetirizine is an over-the-counter non-sedating antihistaminic agent commonly used to treat allergic diseases. To our knowledge, there are only 2 case reports of ALI associated with the use of levocetirizine.2,3 The mechanism behind the process is not well understood.

CASE REPORT

A 67-year-old man with a medical history of osteoarthritis, allergic rhinitis, and dermatomyositis was referred to the hospital by his primary care physician because of a 2-week history of worsening jaundice and pruritus associated with elevated liver enzymes, as well as hyperchromic urine and hypocholic stool. One month before the beginning of the symptoms, routine laboratory tests revealed normal liver enzymes.

The patient had a remote history of tobacco use and reported drinking a glass of wine only on rare occasions. He denied using recreational drugs or herbal supplements and reported no recent travels. His medications were acetaminophen, esomeprazole, and levocetirizine, which he took as needed. He reported that he had previously been taking levocetirizine, but never for more than 2 consecutive days. However, 3 weeks before presentation, he took levocetirizine 5 mg daily for 11 consecutive days for symptoms of allergic rhinitis. He stopped the medication when he began noticing jaundice. The physical examination revealed scleral icterus, jaundice, and mild hepatomegaly without asterixis or other signs of hepatic encephalopathy. There were no palpable lymph nodes or tonsillar exudates.

Laboratory tests on admission revealed aspartate transaminase 1,170 IU/L, alanine transaminase 1,352 IU/L, alkaline phosphatase 130 IU/L, total bilirubin 19.5 mg/dL, direct bilirubin 15.4 mg/dL, albumin 2.1 g/dL, and international normalized ratio 1.6. Serological markers for human immunodeficiency virus, herpes simplex types 1 and 2, and hepatitis viruses A, B, C, D, and E were negative. Polymerase chain reaction test for varicella zoster, cytomegalovirus, human herpesvirus 6 types A and B, and hepatitis B and C viruses was negative. The Epstein-Barr virus antibody to viral capsid antigen was negative for the immunoglobulin M and positive for the immunoglobulin G. The Epstein-Barr virus real-time polymerase chain reaction was weakly positive (1,036 IU/mL; plasma log 3.02). This was deemed to be a weak reactivation of a past subclinical infection and not an acute infection. Ceruloplasmin, iron saturation, thyroid-stimulating hormone, and alpha-1-antitrypsin levels were within normal limits. Serum antimitochondrial
antibody, anti-liver-kidney microsome antibody, and anti-
soluble liver antigen antibody were negative. The antinuclear
antibody was found to be positive (1:640, nucleolar pattern), but
this was consistent with previous tests.

An abdominal ultrasound showed no evidence of choledolithiasis,
biliary ductal obstruction, or hepatic parenchymal disease, and
the Doppler study revealed patent hepatic veins. The abdominal
magnetic resonance imaging with and without contrast showed
evidence of periportal edema. Liver biopsy was performed with
results indicative of acute DILI (Figure 1). Because of high
clinical suspicion of acute DILI, the patient was started on
prednisone 60 mg daily, and within 2 days, both the symptoms
and the levels of transaminases enzymes improved dramatically
(Figure 2).

DISCUSSION

Our case illustrates a highly probable association between ALI
and the use of levocetirizine according to the Roussel Uclaf
Causality Assessment Method based on a score of 9.4 DILI can
be classified according to the biochemical pattern of the liver
enzymes abnormalities into hepatocellular, cholestatic, and
a mixed pattern. A different classification based on the
pathophysiological mechanisms of drug-related injury
distinguishes an “intrinsic” from an “idiosyncratic” hepatotoxicity. Although the first has been proven to be dose de-
pendent and predictable in human and animal models, the
second one is rare, typically unrelated to the dose and has
a variable latency of onset.5 The mechanisms of idiosyncratic
DILI are not completely understood and seem to be hetero-
geous. Genetic and immunologic factors may play a role; it
is possible that a deficiency of drug-metabolizing enzymes
could trigger an abnormal immune response, and studies
showed that specific human leukocyte antigen alleles could
impact the severity and biochemical pattern of the liver injury
in patients who developed an idiosyncratic DILI after the
exposure to amoxicillin-clavulanate.5,6 However, other
mechanisms may be involved as well, including some that
could be dose dependent.7 Interestingly and in conformity
with this observation, the patient in our case had been taking
levocetirizine multiple times in the past, but always for very
short periods and developed a clinically relevant liver injury
only when he took it for 11 consecutive days.

Figure 1. (A) Low-power view of hematoxylin and eosin (H&E) stain of liver biopsy showing evidence of portal inflammation. The lobular
parenchyma shows multifocal inflammatory infiltrates and acidophil bodies. Neither hepatocyte rosettes nor severe necrosis are seen. (B)
Mid-power view of H&E stain showing the periportal inflammation composed of lymphocytes, scattered plasma cells, eosinophils, and
neutrophils. The lobular parenchyma shows mixed inflammatory infiltrates, but eosinophils are not prominent. Intrahepatic cholestasis and
prominent cholestatic injury are seen as well. (C) Reticulin-stain showing intralobular and periportal collapse (arrow). (D) Trichrome stain
showing mild increase in periportal fibrosis (arrow).
Ultimately, the diagnosis of idiosyncratic DILI relies on the exclusion of other etiologies. After having ruled out other possible causes of ALI, we concluded that the most likely diagnosis was idiosyncratic levocetirizine-induced liver injury based on the timing of the administration of the drug and the documented improvement of clinical and laboratory parameters after the patient stopped taking it. The histological findings were found to be similar to another reported case of levocetirizine-induced liver injury, which further supports the diagnosis. Steroids have been proposed as potentially effective to hasten recovery or prevent the progression to ALF based on the current evidence available on the pathophysiology and the role played by immunological mechanisms in DILI: however, high-quality data to support this are lacking. Nevertheless, corticosteroids are commonly used in the treatment of DILI and ALF: data from the Drug-Induced Liver Injury Network show that they were used in the 82% of the patients who died or underwent liver transplantation and 36.6% of the patients alive with native liver at 6 months.

A retrospective study by Hou et al in 70 patients with DILI showed that corticosteroid use was associated with shorter recovery time and fewer deaths or development of chronic liver disease. Similar findings were observed in another retrospective study by Hu et al in patients with severe DILI. Other anecdotal reports described clinical improvements with steroids in severe DILI. Conversely, a retrospective study conducted by Pang et al did not show improvements in recovery time or resolution rate in 32 patients with acute DILI treated with steroids compared with the nonsteroid group, and other retrospective studies in patients with drug-induced ALF failed to show any benefit. An approach proposed by Hu and Xie is to consider the use of corticosteroids in patients with severe DILI (defined by total bilirubin level greater than 5 times the upper limits of normal, with or without an internal normalized ratio \( \geq 1.5 \)), while avoiding them in cases of ALF. In such cases, the condition may be too critical, and there is no evidence that steroid use improves prognosis. Because in mild to moderate DILI, the risk of progression to ALF is considered to be low, the discontinuation of the drug is usually sufficient. Future high-quality controlled trials should further investigate the role of steroids in DILI to better define their possible clinical utility.

DISCLOSURES

Author contributions: G. Annunziata and M. Barbara analyzed the data and wrote the manuscript. I. Mayuko revised the manuscript. G. Annunziata is the article guarantor.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Received April 8, 2019; Accepted June 26, 2019

REFERENCES

1. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947–54.
2. Ekiz F, Yuksel I, Ekiz O, Coban S, Basar O, Yuksel O. Levocetirizine induced hepatotoxicity in a patient with chronic urticaria. Ann Hepatol. 2011;10(2):237–8.
3. Jung MC, Kim JK, Cho JY, et al. A case of levocetirizine-induced liver injury. Clin Mol Hepatol. 2016;22(4):495–8.
4. Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of International Consensus Meetings: Application to drug-induced liver injuries. *J Clin Epidemiol.* 1993;46(11):1323–30.

5. Ye H, Nelson LJ, Gómez Del Moral M, Martínez-Naves E, Cubero FJ. Dissecting the molecular pathophysiology of drug-induced liver injury. *World J Gastroenterol.* 2018;24(13):1373–85.

6. Stephens C, López-Nevo MA, Ruiz-Cabello F, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. *PLoS One.* 2013;8(7):e68111.

7. Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: Current concepts. *Pharmacol Rev.* 2013;65(2):779–808.

8. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, ACG clinical guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. *Am J Gastroenterol.* 2014;109(7):950–66; quiz 967.

9. Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. *Gastroenterology.* 2014;147(1):96–108.e4.

10. Hou FQ, Zeng Z, Wang GQ. Hospital admissions for drug-induced liver injury: Clinical features, therapy, and outcomes. *Cell Biochem Biophys.* 2012;64(2):77–83.

11. Hu PF, Wang PQ, Chen H, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. *J Dig Dis.* 2016;17(9):618–27.

12. Herrero-Herrero JJ, García-Aparicio J. Corticosteroid therapy in a case of severe cholestatic hepatitis associated with amoxicillin-clavulanate. *J Med Toxicol.* 2010;6(4):420–3.

13. Wee A, Dechene A, Herzer K, et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. *Digestion.* 2011;84(1):54–9.

14. Randomised trial of steroid therapy in acute liver failure. Report from the European Association for the Study of the Liver (EASL). *Gut.* 1979;20(7):620–3.

15. Karkhanis J, Verna EC, Chang MS, et al. Steroid use in acute liver failure. *Hepatology.* 2014;59(2):612–21.

16. Rakela J, Mosley JW, Edwards VM, Govindarajan S, Alpert E. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. *Dig Dis Sci.* 1991;36(9):1223–8.

17. Hu PF, Xie WF. Corticosteroid therapy in drug-induced liver injury: Pros and cons. *J Dig Dis.* 2019;20(3):122–6.